tbuckley/cabot-search huggingface dataset:
Two kinds of respect for two kinds of contempt: Why contempt can be both a sentiment and an emotion
Authors: Florian Cova, Julien Deonna, David Sander, Fabrice Teroni
Journal: Behavioral and Brain Sciences (2017)

Abstract Gervais &amp; Fessler argue that because contempt is a sentiment, it cannot be an emotion. However, like many affective labels, it could be that “contempt” refers both to a sentiment and to a distinct emotion. This possibility is made salient by the fact that contempt can be defined by contrast with respect, but that there are different kinds of respect.
Kidney and Blood Catalase Activity of Tumor-Bearing Animals
Authors: Greenstein, Jesse P., Andervont, Howard B., Thompson, J. W.
Journal: JNCI Journal of the National Cancer Institute (1942)

Journal Article Kidney and Blood Catalase Activity of Tumor-Bearing Animals Get access Jesse P. Greenstein, Jesse P. Greenstein senior biochemist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar Howard B. Andervont, Howard B. Andervont principal biologist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar J. W. Thompson J. W. Thompson associate pharmacologist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 2, Issue 6, June 1942, Pages 589–594, https://doi.org/10.1093/jnci/2.6.589 Published: 01 June 1942
Should we treat acute hepatitis C? A decision and cost‐effectiveness analysis
Authors: Emily D. Bethea, Qiushi Chen, Chin Hur, Raymond T. Chung, Jagpreet Chhatwal
Journal: Hepatology (2017)

It is not standard practice to treat patients with acute hepatitis C virus (HCV) infection. However, as the incidence of HCV in the United States continues to rise, it may be time to re‐evaluate acute HCV management in the era of direct‐acting antiviral (DAA) agents. In this study, a microsimulation model was developed to analyze the trade‐offs between initiating HCV therapy in the acute versus chronic phase of infection. By simulating the lifetime clinical course of patients with acute HCV infection, we were able to project long‐term outcomes such as quality‐adjusted life years (QALYs) and costs. We found that treating acute HCV versus deferring treatment until the chronic phase increased QALYs by 0.02 and increased costs by $483 in patients not at risk of transmitting HCV. The resulting incremental cost‐effectiveness ratio was $19,991 per QALY, demonstrating that treatment of acute HCV was cost‐effective using a willingness‐to‐pay threshold of $100,000 per QALY. In patients at risk of transmitting HCV, treating acute HCV became cost‐saving, increasing QALYs by 0.03 and decreasing costs by $3,655. Conclusion: Immediate treatment of acute HCV with DAAs can improve clinical outcomes and be highly cost‐effective or cost‐saving compared with deferring treatment until the chronic phase of infection. If future studies continue to demonstrate effective HCV cure with shorter 6‐week treatment duration, then it may be time to revisit current HCV guidelines to incorporate recommendations that account for the clinical and economic benefits of treating acute HCV in the era of DAAs. (H epatology 2018;67:837–846)
Sorveglianza dell'influenza in Europa: ottobre 1999 - febbraio 2000
Authors: K Mantey, A Mosnier
Journal: Eurosurveillance (2000)

La sorveglianza dell'influenza, condotta dall'EISS (European Influenza Surveillance Scheme) durante la stagione invernale 1999-2000, mostra che l'influenza ha colpito la maggior parte degli 11 paesi partecipanti e che e stata particolarmente attiva nel dicembre 1999 e nel gennaio 2000. Il virus dell'influenza A(H3N2), responsabile di una delle tre maggiori epidemie degli ultimi dieci anni in alcuni paesi appartenenti all'area coperta dall'EISS, ha avuto un'ampia diffusione. E' stato particolarmente attivo in Belgio, nella Repubblica Ceca, in Francia, in Germania, in Italia, nei Paesi Bassi, in Spagna e in Svizzera. La mancanza di una definizione comune di caso continua ad ostacolare il confronto dei dati e ora una delle priorita chiave nello sviluppo dell'EISS e la standardizzazione dei principali indicatori raccolti e delle soglie epidemiche.
Factors That Contributed to Black-White Disparities in Survival Among Nonelderly Women With Breast Cancer Between 2004 and 2013
Authors: Ahmedin Jemal, Anthony S. Robbins, Chun Chieh Lin, W. Dana Flanders, Carol E. DeSantis, Elizabeth M. Ward, Rachel A. Freedman
Journal: Journal of Clinical Oncology (2017)

Purpose To estimate the contribution of differences in demographics, comorbidity, insurance, tumor characteristics, and treatment to the overall mortality disparity between nonelderly black and white women diagnosed with early-stage breast cancer. Patients and Methods Excess relative risk of all-cause death in black versus white women diagnosed with stage I to III breast cancer, expressed as a percentage and stratified by hormone receptor status for each variable (demographics, comorbidity, insurance, tumor characteristics, and treatment) in sequentially, propensity-scored, optimally matched patients by using multivariable hazard ratios (HRs). Results We identified 563,497 white and black women 18 to 64 years of age diagnosed with stage I to III breast cancer from 2004 to 2013 in the National Cancer Data Base. Among women with hormone receptor-positive disease, who represented 78.5% of all patients, the HR for death in black versus white women in the demographics-matched model was 2.05 (95% CI, 1.94 to 2.17). The HR decreased to 1.93 (95% CI, 1.83 to 2.04), 1.54 (95% CI, 1.47 to 1.62), 1.30 (95% CI, 1.24 to 1.36), and 1.25 (95% CI, 1.19 to 1.31) when sequentially matched for comorbidity, insurance, tumor characteristics, and treatment, respectively. These factors combined accounted for 76.3% of the total excess risk of death in black patients; insurance accounted for 37.0% of the total excess, followed by tumor characteristics (23.2%), comorbidities (11.3%), and treatment (4.8%). Results generally were similar among women with hormone receptor-negative disease, although the HRs were substantially smaller. Conclusion Matching by insurance explained one third of the excess risk of death among nonelderly black versus white women diagnosed with early-stage breast cancer; matching by tumor characteristics explained approximately one fifth of the excess risk. Efforts to focus on equalization of access to care could substantially reduce ethnic/racial disparities in overall survival among nonelderly women diagnosed with breast cancer.
TCT-501 Echocardiographic Findings of Transcatheter Mitral Valve-in-Valve Therapy VS. Re-do Surgical MVR in Patients with Previous Mitral Prosthetic Valves
Authors: Norihiko Kamioka, Vasilis Babaliaros, Michael Morse, Tiberio Frisoli, Jose Miguel Iturbe, Frank Corrigan, Jessica Forcillo, Hope Caughron, Andy Dong, Chandan Devireddy, William O'Neill, Gaetano Paone, Dee Dee Wang, Vinod Thourani, Adam Greenbaum
Journal: Journal of the American College of Cardiology (2017)
Peptidoglycan-Sensing Receptors Trigger the Formation of Functional Amyloids of the Adaptor Protein Imd to Initiate Drosophila NF-κB Signaling
Authors: Anni Kleino, Nancy F. Ramia, Gunes Bozkurt, Yanfang Shen, Himani Nailwal, Jing Huang, Johanna Napetschnig, Monique Gangloff, Francis Ka-Ming Chan, Hao Wu, Jixi Li, Neal Silverman
Journal: Immunity (2017)
Varicella Zoster Virus–Specific T Cell Responses in Untreated Giant Cell Arteritis: Comment on the Article by England et al
Authors: Marc B. Bigler, Julia R. Hirsiger, Mike Recher, Matthias Mehling, Thomas Daikeler, Christoph T. Berger
Journal: Arthritis & Rheumatology (2017)

Giant cell arteritis (GCA) is a large vessel vasculitis of unknown cause. Infections were long suspected as potential disease triggers, yet a disease causing pathogen has not been identified to date(1). Recently, several studies reported Varicella zoster virus (VZV) particles in artery biopsies(2). Alike other herpes viruses, VZV has a very high prevalence, remaining dormant in a latent stage controlled by the immune system. Loss of T cell-mediated viral control results in herpes zoster (or shingles).

This article is protected by copyright. All rights reserved.
De la diversité des intoxications alimentaires et des sources de contamination
Authors: N Noah
Journal: Eurosurveillance (1999)

Les trois formes tres distinctes d’intoxications alimentaires decrites dans ce numero d’Eurosurveillance illustrent l’extraordinaire faculte des organismes a survivre et a provoquer des maladies. Clostridium botulinum est un organisme qui produit une toxine (laquelle est d’ailleurs relativement facile a detruire par la chaleur) dans certaines conditions environnementales inhabituelles et bien precises. L’article sur le botulisme en Pologne, ainsi que ceux publies dans le numero special de janvier, montrent combien ces conditions, bien que rares, sont encore repandues. Lors d’infections a Salmonella enteritidis les œufs ou la volaille sont souvent en cause. Aux termes d’une investigation menee en Grece, il s’est avere que le vehicule de l’infection etait vraisemblablement une mayonnaise a base d’œufs crus conserves a 15°C. Cela montre combien la contamination des œufs de poule par ce microorganisme est repandue en Europe. Cependant, aucune salmonelle n’a pu etre mise en evidence dans les œufs provenant de l’elevage approvisionnant le restaurant.
TCT-696 Multi-center analysis of Score predicted vs. Observed survival up to 5-year after MitraClip in patients with symptomatic heart failure and significant Functional Mitral Regurgitation
Authors: Maurizio Taramasso, Cosmo Godino, Andrea Scotti, Marianna Adamo, Marco Russo, Mauro Chiarito, Carlo Andrea Pivato, Luca Baldetti, Andrea Munafò, Anna Salerno, Alberto Cappelletti, Valeria Magni, Stefano Stella, Gabriele Fragasso, Matteo Montorfano, Eustachio Agricola, Federica Ettori, Alberto Margonato, Antonio Colombo, Francesco Maisano
Journal: Journal of the American College of Cardiology (2017)
Association of Distinct Fine Specificities of Anti−Citrullinated Peptide Antibodies With Elevated Immune Responses to <i>Prevotella intermedia</i> in a Subgroup of Patients With Rheumatoid Arthritis and Periodontitis
Authors: Anja Schwenzer, Anne‐Marie Quirke, Anna M. Marzeda, Alicia Wong, Anna B. Montgomery, Harlan R. Sayles, Sigrun Eick, Katarzyna Gawron, Maria Chomyszyn‐Gajewska, Katarzyna Łazarz‐Bartyzel, Simon Davis, Jan Potempa, Benedikt M. Kessler, Roman Fischer, Patrick J. Venables, Jeffrey B. Payne, Ted R. Mikuls, Kim S. Midwood
Journal: Arthritis & Rheumatology (2017)

Objective In addition to the long‐established link with smoking, periodontitis ( PD ) is a risk factor for rheumatoid arthritis ( RA ). This study was undertaken to elucidate the mechanism by which PD could induce antibodies to citrullinated peptides ( ACPA s), by examining the antibody response to a novel citrullinated peptide of cytokeratin 13 ( CK ‐13) identified in gingival crevicular fluid ( GCF ), and comparing the response to 4 other citrullinated peptides in patients with RA who were well‐characterized for PD and smoking. Methods The citrullinomes of GCF and periodontal tissue from patients with PD were mapped by mass spectrometry. ACPA s of CK 13 ( cCK 13), tenascin‐C ( cTNC 5), vimentin ( cVIM ), α‐enolase ( CEP ‐1), and fibrinogen β ( cFIB β) were examined by enzyme‐linked immunosorbent assay in patients with RA (n = 287) and patients with osteoarthritis (n = 330), and cross‐reactivity was assessed by inhibition assays. Results A novel citrullinated peptide cCK 13‐1 ( 444 TSNASGR ‐Cit‐ TSDV ‐Cit‐ RP 458 ) identified in GCF exhibited elevated antibody responses in RA patients (24%). Anti– cCK 13‐1 antibody levels correlated with anti– cTNC 5 antibody levels, and absorption experiments confirmed this was not due to cross‐reactivity. Only anti– cCK 13‐1 and anti‐ cTNC 5 were associated with antibodies to the periodontal pathogen Prevotella intermedia ( P = 0.05 and P = 0.001, respectively), but not with antibodies to Porphyromonas gingivalis arginine gingipains. Levels of antibodies to CEP ‐1, cFIB β, and cVIM correlated with each other, and with smoking and shared epitope risk factors in RA. Conclusion This study identifies 2 groups of ACPA fine specificities associated with different RA risk factors. One is predominantly linked to smoking and shared epitope, and the other links anti– cTNC 5 and cCK 13‐1 to infection with the periodontal pathogen P intermedia .
The WHO public health approach to HIV treatment and care: looking back and looking ahead
Authors: Nathan Ford, Andrew Ball, Rachel Baggaley, Marco Vitoria, Daniel Low-Beer, Martina Penazzato, Lara Vojnov, Silvia Bertagnolio, Vincent Habiyambere, Meg Doherty, Gottfried Hirnschall
Journal: The Lancet Infectious Diseases (2017)
TCT-85 Contemporary Outcomes of Isolated Bioprosthetic Tricuspid Valve Replacement: A Benchmark for Transcatheter Tricuspid Valve Replacement
Authors: Sami Aljohani, Fahad Alqahtani, Tatiana Busu, Ahmad Almustafa, Akram Kawsara, Mohamad Alkhouli
Journal: Journal of the American College of Cardiology (2017)
A retroperitoneal mass confirmed as a pancreatic adenosquamous carcinoma by endoscopic ultrasound-guided fine-needle aspiration
Authors: César Lopes, Antônio Dal Pizzol Júnior, Karen Escamilla, Antônio Hartmann
Journal: Endoscopy (2017)

Adenosquamous carcinoma is a rare subtype of pancreatic adenocarcinoma, accounting for less than 4 % of all exocrine pancreatic malignancies and representing a ductal adenocarcinoma mixed with at least 30 % of malignant squamous cells [1] [2] [3]. Herein, we report a patient with a retroperitoneal mass in whom endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) and immunohistochemical evaluation confirmed a pancreatic adenosquamous carcinoma ([Video 1]).
Linking Dermatology, Neurology, and Psychiatry—Interdisciplinary Contributions of Ian Bruce Sneddon
Authors: Connie R. Shi, Vinod E. Nambudiri
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
An epithelial-mesenchymal transition (EMT) gene signature to predict resistance to EGFR inhibition and AXL identification as a therapeutic target in head and neck squamous cell carcinoma.
Authors: Robert Cardnell, Lixia Diao, Jing Wang, David Bearss, Steven Warner, You Hong Fan, Uma Giri, Michael D. Story, John N. Weinstein, Kevin R. Coombes, Michelle D. Williams, The Cancer Genome Atlas Reseach Network, Ignacio Ivan Wistuba, Gordon B. Mills, Jeffrey Myers, William Nassib William, K. Kian Ang, John Heymach, Lauren Averett Byers
Journal: Journal of Clinical Oncology (2013)

6011 Background: Epithelial-mesenchymal transition (EMT) has been associated with EGFR inhibitor resistance in preclinical studies of head and neck squamous cell carcinoma (HNSCC). Recently, we developed an EMT signature that predicts EGFR inhibitor resistance in lung cancer. Using this signature, we explored the association between EMT and drug response in HNSCC, focusing on the tyrosine kinase Axl as a potential therapeutic target. Methods: We conducted an integrated molecular and drug response analysis in HNSCC. A 76-gene EMT signature previously developed and validated in lung cancer was tested in HNSCC cell lines (n&gt;50) and patient tumors from The Cancer Genome Atlas (TCGA) (n=113) and a MDACC cohort (n=105). Reverse phase protein array (RPPA) and proliferation assays were used to measure protein expression and sensitivity to erlotinib and the Axl inhibitors SGI-7079 and TP-0930. Results: The EMT signature identified distinct epithelial and mesenchymal subsets of HNSCC among cell lines and patient tumors. RPPA experiments revealed higher protein levels of the receptor tyrosine kinase Axl, vimentin, and N-cadherin and lower expression of E-cadherin and beta-catenin in mesenchymal HNSCC (p-values &lt;0.02). Elevated Axl expression was also associated with significantly shorter overall survival in patients with locally advanced HNSCC (p&lt;0.001 in TCGA cohort; p=0.003 MDACC). Consistent with previous studies, mesenchymal HNSCC cells exhibited resistance to erlotinib (IC50 &gt;10μM); however, we discovered that mesenchymal HNSCC were highly sensitive to two Axl inhibitors, SGI-7079 and TP-0930 (IC50s ≤1.2μM and 0.2uM, respectively). Conclusions: Our EMT gene expression signature identified discrete epithelial and mesenchymal subgroups of HNSCC. Mesenchymal HNSCC cells expressed higher levels of Axl protein and exhibited sensitivity to Axl inhibition, but resistance to erlotinib. These results highlight differences in drug response between epithelial and mesenchymal cancers and support Axl as a potential therapeutic target and predictive marker of EGFR inhibitor resistance in HNSCC. (Funded in part by 5 P50 CA097007-10)
Atrial Fibrillation Burden in Young Patients With Congenital Heart Disease
Authors: Zacharias Mandalenakis, Annika Rosengren, Georg Lappas, Peter Eriksson, Thomas Gilljam, Per-Olof Hansson, Kristofer Skoglund, Maria Fedchenko, Mikael Dellborg
Journal: Circulation (2017)

Patients with congenital heart disease (CHD) are assumed to be vulnerable to atrial fibrillation (AF) as a result of residual shunts, anomalous vessel anatomy, progressive valvulopathy, hypertension, and atrial scars from previous heart surgery. However, the risk of developing AF and the complications associated with AF in children and young adults with CHD have not been compared with those in control subjects.Data from the Swedish Patient and Cause of Death registers were used to identify all patients with a diagnosis of CHD who were born from 1970 to 1993. Each patient with CHD was matched by birth year, sex, and county with 10 control subjects from the Total Population Register in Sweden. Follow-up data were collected until 2011.Among 21 982 patients (51.6% men) with CHD and 219 816 matched control subjects, 654 and 328 developed AF, respectively. The mean follow-up was 27 years. The risk of developing AF was 21.99 times higher (95% confidence interval, 19.26-25.12) in patients with CHD than control subjects. According to a hierarchical CHD classification, patients with conotruncal defects had the highest risk (hazard ratio, 84.27; 95% confidence interval, 56.86-124.89). At the age of 42 years, 8.3% of all patients with CHD had a recorded diagnosis of AF. Heart failure was the quantitatively most important complication in patients with CHD and AF, with a 10.7% (70 of 654) recorded diagnosis of heart failure.The risk of AF in children and young adults with CHD was 22 times higher than that in matched control subjects. Up to the age of 42 years, 1 of 12 patients with CHD had developed AF, and 1 of 10 patients with CHD with AF had developed heart failure. The patient groups with the most complex congenital defects carried the greatest risk of AF and could be considered for targeted monitoring.
P1.04-005 Efficacy of Photodynamic Therapy Combined with a Guide Sheath Method in Lung Cancer Patients with Endobronchial Stenosis
Authors: Masafumi Misawa, Fumi Suzuki, Satoshi Yamawaki, Ryuta Tsuzuki, Ayumu Otsuki, Kei Nakashima, Satoshi Noma, Masahiro Aoshima
Journal: Journal of Thoracic Oncology (2017)
International Patterns and Trends in Endometrial Cancer Incidence, 1978–2013
Authors: Joannie Lortet-Tieulent, Jacques Ferlay, Freddie Bray, Ahmedin Jemal
Journal: JNCI Journal of the National Cancer Institute (2017)

Cancers of the corpus uteri-primarily of the endometrium-rank as the sixth most common neoplasm in women worldwide. Analyses of the global patterns and trends of uterine cancer rates are needed in view of the ongoing obesity epidemic, a major risk factor for the disease.
Dose-Response Association of CD8<sup>+</sup> Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer
Authors: Ellen L. Goode, Matthew S. Block, Kimberly R. Kalli, Robert A. Vierkant, Wenqian Chen, Zachary C. Fogarty, Aleksandra Gentry-Maharaj, Aleksandra Toloczko, Alexander Hein, Aliecia L. Bouligny, Allan Jensen, Ana Osorio, Andreas D. Hartkopf, Andy Ryan, Anita Chudecka-Glaz, Anthony M. Magliocco, Arndt Hartmann, Audrey Y Jung, Bo Gao, Brenda Y. Hernandez, Brooke L. Fridley, Bryan M. McCauley, Catherine J. Kennedy, Chen Wang, Chloe Karpinskyj, Christiani B. de Sousa, Daniel G. Tiezzi, David L. Wachter, Esther Herpel, Florin Andrei Taran, Francesmary Modugno, Gregg Nelson, Jan Lubinski, Janusz Menkiszak, Jennifer Alsop, Jenny Lester, Jesús García-Donas, Jill Nation, Jillian Hung, José Palacios, Joseph H. Rothstein, Joseph L. Kelley, Jurandyr M. de Andrade, Luis Robles-Díaz, Maria P. Intermaggio, Martin Widschwendter, Matthias W. Beckmann, Matthias Ruebner, Mercedes Jimenez-Linan, Naveena Singh, Oleg Oszurek, Paul R. Harnett, Peter F. Rambau, Peter Sinn, Philipp Wagner, Prafull Ghatage, Raghwa Sharma, Robert P. Edwards, Roberta B. Ness, Sandra Orsulic, Sara Y. Brucker, Sharon E. Johnatty, Teri A. Longacre, Ursula Eilber, Valerie McGuire, Weiva Sieh, Yanina Natanzon, Zheng Li, Alice S. Whittemore, Anna deFazio, Annette Staebler, Beth Y. Karlan, Blake Gilks, David D. Bowtell, Estrid Høgdall, Francisco J. Candido dos Reis, Helen Steed, Ian G. Campbell, Jacek Gronwald, Javier Benítez, Jennifer M. Koziak, Jenny Chang-Claude, Kirsten B. Moysich, Linda E. Kelemen, Linda S. Cook, Marc T. Goodman, María José García, Peter A. Fasching, Stefan Kommoss, Suha Deen, Susanne K. Kjaer, Usha Menon, James D. Brenton, Paul D. P. Pharoah, Georgia Chenevix-Trench, David G. Huntsman, Stacey J. Winham, Martin Köbel, Susan J. Ramus
Journal: JAMA Oncology (2017)

Cytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) participate in immune control of epithelial ovarian cancer; however, little is known about prognostic patterns of CD8+ TILs by histotype and in relation to other clinical factors.